Kim, Hyunki <br/><br/>
Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.  [electronic resource] 

 -  Molecular cancer therapeutics  Feb 2012 
 - 405-15 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-11-0581  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antibodies, Monoclonal--chemistry<br/>Basigin--immunology<br/>Carbocyanines--chemistry<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Drug Therapy, Combination<br/>Female<br/>Fluorodeoxyglucose F18--pharmacokinetics<br/>Humans<br/>Magnetic Resonance Imaging<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, SCID<br/>Microscopy, Fluorescence--methods<br/>Multimodal Imaging--methods<br/>Pancreatic Neoplasms--drug therapy<br/>Positron-Emission Tomography<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--immunology<br/>Tomography, X-Ray Computed<br/>Xenograft Model Antitumor Assays